Compare BioNano Genomics Inc (BNGO) vs Logitech International SA (LOGI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs Logitech International SA — how do they compare? BioNano Genomics Inc trades at $1.18 (market cap $13.66M), while Logitech International SA trades at $103.79 (market cap $14.96B). The key difference: Logitech International SA is far larger — about 1095.2× BioNano Genomics Inc's market cap, and Logitech International SA pays a 1.64% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | LOGI | |
|---|---|---|
Market Cap | $13.66M | $14.96B |
Sector | Health | Technology |
52-Week High | $4.92 | $126.69 |
52-Week Low | $1.06 | $85.84 |
Enterprise Value | $16.26M | $13.30B |
Dividend Yield | — | 1.64% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.195, up 3.02% today, with a bullish technical signal from moving averages but a neutral oscillator stance. The company shows improving financial trends, with net losses narrowing to -$26.40M in 2025 from -$232M in 2023, and recent earnings beats. Revenue stabilized around $29M, while cash flow trends indicate reduced operational cash burn. Analyst sentiment is positive, with 57% buy ratings.
The outlook for BNGO hinges on sustaining revenue growth and achieving profitability, supported by strategic hires and debt retirement. Key risks include persistent negative margins and high cash burn. With a low P/S of 0.31, the stock offers value if execution improves, but investors face volatility from operational challenges and competitive pressures.
Logitech (LOGI) trades at $103.28, down 1.52% on the day, with a bearish technical signal and mixed analyst sentiment. Recent Q1 2027 earnings beat expectations with EPS of $1.85 versus $1.26 expected, driven by tariff refunds and premium demand. However, a semiconductor supplier shutdown poses near-term supply chain risks. The stock shows strong profitability with a net margin of 16.28% and ROE of 35.29%, but valuation multiples like P/E of 19.03 and P/S of 3.1 suggest moderate pricing.
Outlook is cautious due to supply constraints overshadowing solid fundamentals. The consensus price target is $109.75, offering ~6% upside, but investor sentiment is divided with equal buy and sell ratings. Key risks include execution on supply chain mitigation and competitive pressures in the gaming and peripherals market. Near-term performance hinges on resolving supplier issues to meet robust demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About Logitech International SA
Logitech International SA is a Switzerland-based provider of personal computer and mobile accessories for navigation, video communication, and collaboration, smart home, and other applications. Its product portfolio includes mice, keyboards, charging stands, tablet cases, car mounts for mobile devices, remotes, home cameras, home switches, controllers, bluetooth speakers, surround sound, webcams, and conference cameras. It operates in a single segment namely, Peripherals. The firm generates revenue from the Americas, EMEA (Europe, Middle East, Africa), and the Asia Pacific region.
Read more on LOGI →
